Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: Lipocine Q2 EPS $(0.41) Misses $(0.40) Estimate, Sales $622.849K Beat $229.000K Estimate

Author: Benzinga Newsdesk | August 05, 2025 09:11am
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.40) by 2.5 percent. This is a 26.79 percent increase over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $622.849 thousand which beat the analyst consensus estimate of $229.000 thousand by 171.99 percent. This is a 595.42 percent increase over sales of $89.565 thousand the same period last year.

Posted In: LPCN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist